AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 300.2 USD | -1.85% |
|
-4.66% | +4.23% |
| 28/05 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
| 28/05 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
| Sales 2024 * | 33B 2,749B | Sales 2025 * | 33.96B 2,829B | Capitalization | 161B 13,415B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.13B 344B | Net income 2025 * | 6.52B 543B | EV / Sales 2024 * | 6.36 x |
| Net Debt 2024 * | 48.72B 4,058B | Net Debt 2025 * | 43.88B 3,655B | EV / Sales 2025 * | 6.03 x |
| P/E ratio 2024 * |
37.8
x | P/E ratio 2025 * |
24.3
x | Employees | 26,700 |
| Yield 2024 * |
3.08% | Yield 2025 * |
3.33% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -1.85% | ||
| 1 week | -4.66% | ||
| Current month | +9.58% | ||
| 1 month | +11.19% | ||
| 3 months | +8.19% | ||
| 6 months | +13.06% | ||
| Current year | +4.23% |
1 week
298.31
311.99
1 month
272.35322.60
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.68329.72
10 years
114.93329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/01 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/19/23 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/17/03 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/16/14 |
Robert Williams
BRD | Director/Board Member | 75 | 17/14/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 116 M€ | +14.55% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/24/28 | 300.2 | -1.85% | 2,636,709 |
| 24/24/24 | 305.8 | -0.22% | 2,425,864 |
| 23/24/23 | 306.5 | -0.94% | 2,139,729 |
| 22/24/22 | 309.4 | -1.73% | 2,849,114 |
| 21/24/21 | 314.8 | +0.10% | 1,705,945 |
Delayed Quote Nasdaq, May 29, 2024 at 01:30 am IST
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
31/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
300.2
USD
Average target price
316.3
USD
Spread / Average Target
+5.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.23% | 161B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +12.94% | 238B | |
| +6.92% | 204B | |
| -6.46% | 203B | |
| -1.70% | 160B | |
| -2.12% | 120B |
- Stock Market
- Equities
- AMGN Stock
